Search Results - "DALTON, William"

A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study by Scott, Jacob G, MD, Berglund, Anders, PhD, Schell, Michael J, Prof, Mihaylov, Ivaylo, PhD, Fulp, William J, MS, Yue, Binglin, MS, Welsh, Eric, PhD, Caudell, Jimmy J, MD, Ahmed, Kamran, MD, Strom, Tobin S, MD, Mellon, Eric, MD, Venkat, Puja, MD, Johnstone, Peter, Prof, Foekens, John, Prof, Lee, Jae, Prof, Moros, Eduardo, Prof, Dalton, William S, Prof, Eschrich, Steven A, PhD, McLeod, Howard, Prof, Harrison, Louis B, Prof, Torres-Roca, Javier F, Dr

“…Summary Background Despite its common use in cancer treatment, radiotherapy has not yet entered the era of precision medicine, and there have been no…”
Get full text

The Bone Marrow Microenvironment as a Tumor Sanctuary and Contributor to Drug Resistance by Meads, Mark B, Hazlehurst, Lori A, Dalton, William S

“…The bone marrow microenvironment facilitates the survival, differentiation, and proliferation of hematopoietic cells. These cells are supported by…”
Get full text

MicroRNA-155 Is Regulated by the Transforming Growth Factor β/Smad Pathway and Contributes to Epithelial Cell Plasticity by Targeting RhoA by Kong, William, Yang, Hua, He, Lili, Zhao, Jian-jun, Coppola, Domenico, Dalton, William S., Cheng, Jin Q.

“…Article Usage Stats Services MCB Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Optimizing Cancer Treatment Using Game Theory: A Review by Stanková, Katerina, Brown, Joel S, Dalton, William S, Gatenby, Robert A

“…While systemic therapy for disseminated cancer is often initially successful, malignant cells, using diverse adaptive strategies encoded in the human genome,…”
Get more information

Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma by Zhao, Xiaohong, Lwin, Tint, Silva, Ariosto, Shah, Bijal, Tao, Jiangchuan, Fang, Bin, Zhang, Liang, Fu, Kai, Bi, Chengfeng, Li, Jiannong, Jiang, Huijuan, Meads, Mark B., Jacobson, Timothy, Silva, Maria, Distler, Allison, Darville, Lancia, Zhang, Ling, Han, Ying, Rebatchouk, Dmitri, Di Liberto, Maurizio, Moscinski, Lynn C., Koomen, John M., Dalton, William S., Shain, Kenneth H., Wang, Michael, Sotomayor, Eduardo, Tao, Jianguo

“…The novel Bruton’s tyrosine kinase inhibitor ibrutinib has demonstrated high response rates in B-cell lymphomas; however, a growing number of ibrutinib-treated…”
Get full text

Patient Enrichment for Precision‐Based Cancer Clinical Trials: Using Prospective Cohort Surveillance as an Approach to Improve Clinical Trials by Dalton, William S., Sullivan, Daniel, Ecsedy, Jeffrey, Caligiuri, Michael A.

“…Technological advances have led to the identification of biomarkers and development of novel target‐based therapies. While some novel therapies have improved…”
Get full text

microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma by Zhao, Jian-Jun, Lin, Jianhong, Lwin, Tint, Yang, Hua, Guo, Jianping, Kong, William, Dessureault, Sophie, Moscinski, Lynn C., Rezania, Dorna, Dalton, William S., Sotomayor, Eduardo, Tao, Jianguo, Cheng, Jin Q.

“…Mantle cell lymphoma (MCL) is one of the most aggressive B-cell lymphomas. Although several protein-coding genes are altered, expression signature and…”
Get full text

Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas by Zhang, Xinwei, Zhao, Xiaohong, Fiskus, Warren, Lin, Jianhong, Lwin, Tint, Rao, Rekha, Zhang, Yizhuo, Chan, John C, Fu, Kai, Marquez, Victor E, Chen-Kiang, Selina, Moscinski, Lynn C, Seto, Edward, Dalton, William S, Wright, Kenneth L, Sotomayor, Eduardo, Bhalla, Kapil, Tao, Jianguo

“…We investigated the transcriptional and epigenetic repression of miR-29 by MYC, HDAC3, and EZH2 in mantle cell lymphoma and other MYC-associated lymphomas. We…”
Get full text

BCL2 Amplicon Loss and Transcriptional Remodeling Drives ABT-199 Resistance in B Cell Lymphoma Models by Zhao, Xiaohong, Ren, Yuan, Lawlor, Matthew, Shah, Bijal D., Park, Paul M.C., Lwin, Tint, Wang, Xuefeng, Liu, Kenian, Wang, Michelle, Gao, Jing, Li, Tao, Xu, Mousheng, Silva, Ariosto S., Lee, Kaplan, Zhang, Tinghu, Koomen, John M., Jiang, Huijuan, Sudalagunta, Praneeth R., Meads, Mark B., Cheng, Fengdong, Bi, Chengfeng, Fu, Kai, Fan, Huitao, Dalton, William S., Moscinski, Lynn C., Shain, Kenneth H., Sotomayor, Eduardo M., Wang, Gang Greg, Gray, Nathanael S., Cleveland, John L., Qi, Jun, Tao, Jianguo

“…Drug-tolerant “persister” tumor cells underlie emergence of drug-resistant clones and contribute to relapse and disease progression. Here we report that…”
Get full text

PLK1 stabilizes a MYC-dependent kinase network in aggressive B cell lymphomas by Ren, Yuan, Bi, Chengfeng, Zhao, Xiaohong, Lwin, Tint, Wang, Cheng, Yuan, Ji, Silva, Ariosto S, Shah, Bijal D, Fang, Bin, Li, Tao, Koomen, John M, Jiang, Huijuan, Chavez, Julio C, Pham, Lan V, Sudalagunta, Praneeth R, Wan, Lixin, Wang, Xuefeng, Dalton, William S, Moscinski, Lynn C, Shain, Kenneth H, Vose, Julie, Cleveland, John L, Sotomayor, Eduardo M, Fu, Kai, Tao, Jianguo

“…Concordant activation of MYC and BCL-2 oncoproteins in double-hit lymphoma (DHL) results in aggressive disease that is refractory to treatment. By integrating…”
Get full text

Cancer Biomarkers--An Invitation to the Table by Dalton, William S, Friend, Stephen H

“…The allure of the emerging genomic technologies in cancer is their ability to generate new biomarkers that predict how individual cancer patients will respond…”
Get full text

Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy by Nefedova, Yulia, Sullivan, Daniel M., Bolick, Sophia C., Dalton, William S., Gabrilovich, Dmitry I.

“…Drug resistance remains a critical problem in the treatment of patients with multiple myeloma. Recent studies have de-termined that Notch signaling plays a…”
Get full text

β1 Integrin Adhesion Enhances IL-6―Mediated STAT3 Signaling in Myeloma Cells: Implications for Microenvironment Influence on Tumor Survival and Proliferation by SHAIN, Kenneth H, YARDE, Danielle N, MEADS, Mark B, MEI HUANG, JOVE, Richard, HAZLEHURST, Lori A, DALTON, William S

“…Abstract The bone marrow microenvironmental components interleukin (IL)-6 and fibronectin (FN) individually influence the proliferation and survival of…”
Get full text

Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma by Richardson, Paul G, Sonneveld, Pieter, Schuster, Michael W, Irwin, David, Stadtmauer, Edward A, Facon, Thierry, Harousseau, Jean-Luc, Ben-Yehuda, Dina, Lonial, Sagar, Goldschmidt, Hartmut, Reece, Donna, San-Miguel, Jesus F, Bladé, Joan, Boccadoro, Mario, Cavenagh, Jamie, Dalton, William S, Boral, Anthony L, Esseltine, Dixie L, Porter, Jane B, Schenkein, David, Anderson, Kenneth C

“…Bortezomib, an inhibitor of proteasomes (sites of protein degradation in cells), has activity against advanced multiple myeloma. This study compared bortezomib…”
Get full text

Maternal Depressive Symptoms and the Risk of Overweight in Their Children by Wang, Liang, Anderson, James L., Dalton III, William T., Wu, Tiejian, Liu, Xianchen, Zheng, Shimin, Liu, Xuefeng

“…To examine the association between maternal depressive symptoms during early childhood of their offspring and later overweight in the children. Only children…”
Get full text

Environment-mediated drug resistance: a major contributor to minimal residual disease by Dalton, William S, Meads, Mark B, Gatenby, Robert A

“…How does therapeutic resistance affect disease relapse? Here the authors argue that the tumour microenvironment mediates a complex form of de novo drug…”
Get full text

Retraction Notice to: Coordinated Silencing of MYC-Mediated miR-29 by HDAC3 and EZH2 as a Therapeutic Target of Histone Modification in Aggressive B-Cell Lymphomas by Zhang, Xinwei, Zhao, Xiaohong, Fiskus, Warren, Lin, Jianhong, Lwin, Tint, Rao, Rekha, Zhang, Yizhuo, Chan, John C., Fu, Kai, Marquez, Victor E., Chen-Kiang, Selina, Moscinski, Lynn C., Seto, Edward, Dalton, William S., Wright, Kenneth L., Sotomayor, Eduardo, Bhalla, Kapil, Tao, Jianguo

Get full text

Melphalan and Exportin 1 Inhibitors Exert Synergistic Antitumor Effects in Preclinical Models of Human Multiple Myeloma by Turner, Joel G, Cui, Yan, Bauer, Alexis A, Dawson, Jana L, Gomez, Juan A, Kim, Jongphil, Cubitt, Christopher L, Nishihori, Taiga, Dalton, William S, Sullivan, Daniel M

“…High-dose chemotherapy with melphalan followed by autologous transplantation is a first-line treatment for multiple myeloma. Here, we present preclinical…”
Get full text

Personalizing Radiotherapy Prescription Dose Using Genomic Markers of Radiosensitivity and Normal Tissue Toxicity in NSCLC by Scott, Jacob G, Sedor, Geoff, Scarborough, Jessica A, Kattan, Michael W, Peacock, Jeffrey, Grass, G Daniel, Mellon, Eric A, Thapa, Ram, Schell, Michael, Waller, Anthony, Poppen, Sean, Andl, George, Teer, Jamie K, Eschrich, Steven A, Dilling, Thomas J, Dalton, William S, Harrison, Louis B, Fox, Tim, Torres-Roca, Javier F

“…Cancer sequencing efforts have revealed that cancer is the most complex and heterogeneous disease that affects humans. However, radiation therapy (RT), one of…”
Get more information

Implementing personalized medicine in a cancer center by Fenstermacher, David A, Wenham, Robert M, Rollison, Dana E, Dalton, William S

“…In 2006, the Moffitt Cancer Center partnered with patients, community clinicians, industry, academia, and 17 hospitals in the United States to begin a…”
Get full text